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Abstract
Introduction: Nonalcoholic fatty liver disease (NAFLD) is one of the most important causes of liver-related morbidity and
mortality in children. Recently, we have reported the effects of docosahexaenoic acid (DHA), the major dietary long-chain
polyunsaturated fatty acids, in children with NAFLD. DHA exerts a potent anti-inflammatory activity through the G protein-
coupled receptor (GPR)120. Our aim was to investigate in pediatric NAFLD the mechanisms underlying the effects of DHA
administration on histo-pathological aspects, GPR120 expression, hepatic progenitor cell activation and macrophage pool.
Patients and Methods: 20 children with untreated NAFLD were included. Children were treated with DHA for 18 months.
Liver biopsies before and after the treatment were analyzed. Hepatic progenitor cell activation, macrophage pool and
GPR120 expression were evaluated and correlated with clinical and histo-pathological parameters.
Results: GPR120 was expressed by hepatocytes, liver macrophages, and hepatic progenitor cells. After DHA treatment, the
following modifications were present: i) the improvement of histo-pathological parameters such as NAFLD activity score,
ballooning, and steatosis; ii) the reduction of hepatic progenitor cell activation in correlation with histo-pathological
parameters; iii) the reduction of the number of inflammatory macrophages; iv) the increase of GPR120 expression in
hepatocytes; v) the reduction of serine-311-phosphorylated nuclear factor kappa B (NF-kB) nuclear translocation in
hepatocytes and macrophages in correlation with serum inflammatory cytokines.
Conclusions: DHA could modulate hepatic progenitor cell activation, hepatocyte survival and macrophage polarization
through the interaction with GPR120 and NF-kB repression. In this scenario, the modulation of GPR120 exploits a novel
crucial role in the regulation of the cell-to-cell cross-talk that drives inflammatory response, hepatic progenitor cell
activation and hepatocyte survival.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is one of the most
important causes of liver-related morbidity and mortality in
children [1]. NAFLD includes a spectrum of diseases ranging from
simple fatty liver to nonalcoholic steatohepatitis (NASH). NASH
development in children is characterized by intricate interactions
between resident and recruited cells that enable liver damage
progression [1,2]. Interestingly, we demonstrated that hepatic
stem/progenitor cells (HPCs) may be involved in the response of
the liver to oxidative stress in pediatric NAFLD, and their
activation was correlated with fibrosis and NASH [3].
Recently, there has been growing interest in N-3 long-chain
polyunsaturated fatty acids (LC-PUFA) supplementation as
potential treatment for liver steatosis [4,5]. The problems of
adherence to lifestyle interventions to achieve sustainable weight
loss especially in children, and side-effects with pharmacological
agents make of dietary fish oil supplementation a simple and
practical alternative therapy. Fish oil provides a convenient source
of essential N-3 LC-PUFA with few side effects and may directly
reduce hepatic lipogenesis and steatosis [5–7]. We have recently
reported the short-term (6 months) and long-term (up to 24
months) effects of docosahexaenoic acid (DHA), the major dietary
N-3 LC-PUFA, after 6, 12, 18 and 24 months of treatment with
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different concentrations (DHA 250 mg/day and DHA 500 mg/
day) combined with diet and exercise [8,9]. In these studies, algae
DHA supplementation improved liver steatosis in children with
NAFLD and was able to reduce the levels of serum ALT and
triglycerides [8,9].
DHA exerts a potent anti-inflammatory activity through the G
protein-coupled receptor GPR120 [10]; dietary DHA suppresses
hepatic markers of oxidative stress, inflammation and fibrosis [11].
However, its effects on histo-pathological features, as well as its
cellular and molecular mechanisms in pediatric NAFLD remain to
be established.
The aim of this study was to investigate the mechanisms
underlying the effects of DHA administration in pediatric NAFLD
(pNAFLD) on histo-pathological aspects, GPR120 expression,
Macrophage (MW)/Kupffer cell(KC) polarization and HPC
activation.
Patients and Methods
Ethics Statement
The study protocol conformed to the ethical guidelines of the
1975 Declaration of Helsinki. The study was approved by the local
ethics committee (Bambino Gesu` Children’s Hospital IRCCS,
Rome, Italy). A written informed consent was obtained from the
next of kin, caretakers, or guardians on behalf of the children
enrolled in this study.
Patients, Anthropometrics and Laboratory Data
The study was performed on 20 patients from the randomised
controlled clinical trial registered on http://www.clinicaltrials.gov
(Trial identifier NCT00885313) conducted at the Liver Unit of the
Bambino Gesu` Pediatric Hospital (Rome, Italy). For the patients
enrolment the entry criteria were: persistently elevated serum
alanine transaminase (ALT $40 U/l), diffusely hyperechogenic
liver at ultrasonography and liver biopsy consistent with NAFLD.
Furthermore, patients with secondary causes of steatosis, including
alcohol abuse ($140 g/week), total parenteral nutrition, drugs,
hepatitis A, B, C, cytomegalovirus, Epstein-Barr virus infections,
autoimmune liver disease, metabolic liver diseases, Wilson’s
disease, and alpha-1-antitrypsin deficiency were excluded from
the trial. The children included in our analyses showed clinical and
pathological features resembling those seen in our general
pediatric population with NAFLD [12].
These patients were diagnosed with NAFLD through liver
biopsy recommended because of persistently (.6 months) elevated
ALT levels and the presence of an echogenic texture of the liver on
ultrasonography. Furthermore, the patients received no dietary or
other therapeutic treatment regimens before diagnosis.
The clinical indication for biopsy was either to assess the
presence of NASH and the degree of fibrosis or to diagnose other
likely independent or competing liver diseases. Liver biopsy was
performed after an overnight fast by using an automatic core
biopsy 18-gauge needle under general anesthesia and ultrasound
guidance. Two biopsies passing within different liver segments
were performed for each subject.
Patients were treated with DHA 250 mg/day (39% DHA oil
obtained from Schyzochitrium, Martek Biosciences Corporation,
Columbia, MD, USA). Liver biopsy was performed after 18
months of treatment.
Liver specimens from 6 lean, non-diabetic children (boys, 4;
girls, 2; median age: 13 years, range, 12–16 years) without liver
disease were used as controls. Control liver fragments were
obtained from patients who underwent laparotomy or laparo-
scopic procedures (for cholecystectomy), from liver donors
(orthotopic liver transplantation) or incidental ‘‘normal’’ liver
biopsies (children exhibiting persistent/intermittent elevations of
liver enzymes for .6 months).
Weight, height, and body mass index (BMI) were measured
[12]. Alanine and aspartate aminotransferase, gamma-glutamyl-
transpeptidase, total triglycerides and total cholesterol were
evaluated using standard laboratory methods. Insulin was mea-
sured using a radio-immunoassay (Myria Technogenetics, Milan,
Italy). Glucose and insulin were measured at 0, 30, 60, 90 and 120
minutes of an oral glucose tolerance test performed with 1.75
grams of glucose per kilogram of body weight (up to 75 g). The
degree of insulin resistance and sensitivity was determined by the
homeostatic model assessment insulin resistance (HOMA-IR), and
the insulin sensitivity index (ISI) derived from an oral glucose
tolerance test (OGGT), respectively. Data at baseline and after 18
month of treatment were acquired.
Liver Ultrasonography
Liver ultrasonography was performed by an experienced
radiologist using an Acuson Sequoia C512 scanner equipped with
a 15L8 transducer (Universal Diagnostic Solutions, Oceanside,
CA). Steatosis has been graded by a validated score [13]. Absent
steatosis (grade 0) was defined as normal liver echo-texture; mild
steatosis (grade 1) as slight and diffuse increase in fine parenchymal
echoes with normal visualization of diaphragm and portal vein
borders; moderate steatosis (grade 2) as moderate and diffuse
increase in fine echoes with slightly impaired visualization of
diaphragm and portal vein borders; and severe steatosis (grade 3)
as fine echoes with poor or no visualization of diaphragm, portal
vein borders and posterior portion of the right lobe.
Histopathology, Immunohistochemistry (IHC) and
Immunofluorescence (IF)
Steatosis, inflammation, hepatocyte ballooning and fibrosis were
scored using the NAFLD Clinical Research Network (CNR)
criteria [14]. Steatosis, lobular inflammation, and hepatocyte
ballooning were combined to obtain the NAFLD activity score
(NAS). A microscopic diagnosis based on overall injury pattern
(steatosis, hepatocyte ballooning, inflammation) as well as the
presence of additional lesions (e.g. zonality of lesions, portal
inflammation and fibrosis) has been assigned to each case [15].
Accordingly, biopsies were classified into: not steatohepatitis (not-
SH), definite steatohepatitis (definite-SH), borderline zone 1
pattern or borderline zone 3 pattern subcategories [15]. PNHS,
a more adequate score for pNAFLD [16], was also calculated.
Histological analysis was performed by a single pathologist blinded
to clinical and laboratory data.
For IHC and IF, sections were incubated overnight at 4uC with
primary antibodies against cytokeratin (CK)7 (Dako, mouse
monoclonal, code: M7018, dilution: 1:100), EpCAM (Dako,
mouse monoclonal, code: M3525, dilution: 1:100), CD68 (Dako,
mouse monoclonal, code: M0876, dilution: 1:100), GPR120
(Sigma-Aldrich, rabbit polyclonal, code: HPA-042563, dilution:
1:30), and serine-311-phosphorylated NF-kB (p-65NF-kB) pur-
chased from Santa Cruz Biotechnology (goat polyclonal, code: sc-
33039-R, dilution 1:50). For IHC, samples were than incubated
for 20 minutes at room temperature with secondary biotinylated
antibody and, successively, with streptavidin-Horse radish perox-
idase (LSAB+, Dako, code K0690). Diaminobenzidine (Dako,
code K3468) was used as the substrate and the sections were
counterstained with hematoxylin. For double IF staining, non-
specific protein binding was blocked with 5% normal goat serum.
After the incubation with primary antibodies, specimens were
washed and incubated for 1 h with labeled isotype-specific
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secondary antibodies (anti-mouse AlexaFluor-488 and anti-rabbit
Alexafluor-564, Invitrogen) and counterstained with 4,6-diami-
dino-2-phenylindole (DAPI) for visualization of cell nuclei. For all
immunoreactions, negative controls (the primary antibody was
replaced with pre-immune serum) were also included [17].
Sections were examined with a Leica Microsystems DM 4500 B
Microscopy (Weltzlar, Germany) equipped with a Jenoptik Prog
Res C10 Plus Videocam (Jena, Germany). Only biopsies
containing at least 5 portal spaces were considered [18].
The ductular reaction (DR) extension was evaluated on liver
section stained for CK7. Slides were scanned and processed by a
digital scanner (Aperio Scanscope CS System, Aperio Technolo-
gies, Inc). The virtual slide have been visualized and processed by
the software included in the Aperio Scanscope CS System
(ImageScope). An image analysis algorithm, that automatically
analyzes, the digital slides has been used to quantify the area
occupied by CK7 positive cells. The algorithm was applied on the
entire sections. The extent of DR was expressed as the percentage
of the parenchymal area occupied by reactive ductules [19].
Solitary CK7-positive HPCs or those in small clumps that were
localized in the parenchyma or at the portal interface were
included in these counts because they should be considered as a
histological sectioning of bile/reactive ductules through a trans-
verse plane without any unique immunohistochemical markers to
distinguish them from cells within bile/reactive ductules [19].
Cholangiocytes lining the interlobular bile ducts were excluded
from the counts.
The activation of HPC compartment was evaluated by counting
the number of EpCAM-positive cells within the bile/reactive
ductules and expressed as number of positive cells per high power
field (HPF: at 406) [20].
Intermediate hepatocytes (IHs) were defined as cells with sizes
between those of hepatocytes and HPCs (,40 but .6 mm in
diameter), with faint CK-7 immunoreactivity in the cytoplasm and
reinforcement at the plasma membrane7. The presence of IHs was
scored as reported elsewhere: 0 = no IH, 1 = single occasional IHs
and 2= clusters of His [21].
GPR120 expression by EpCAM-positive HPCs or CD68-
positive macrophages was evaluated in serial sections and by
double IF. The number of positive macrophages per HPF was
calculated. GPR120 expression by hepatocytes and HPCs was
semi-quantitatively scored [22]. The nuclear expression of p-
65NF-kB was calculated counting the number of MW/KC or
hepatocytes with positive nuclei. Data were expressed as a
percentage of positive cells. At least 30 lobular fields at 406
magnification were analyzed for each section [3].
Cytokine Assay
Serum levels of pro-inflammatory cytokines were determined
using cytokine-specific ELISA assays. Concentrations were eval-
uated by manufacturing protocols from RayBiotech Inc (Norcross
GA, USA) for IL-1b and IL-6 and from Immundiagnostik (AG,
Bensheim, Germany) for tumour necrosis factor (TNF)-a.
Statistical Methods
Data are indicated as mean6standard deviation (SD). The
Student t test or Mann–Whitney U test was used to determine
differences between groups for normally or not normally
distributed data, respectively. To evaluate the modification of
variables after DHA treatment, the paired-samples T Test was
applied. The Pearson correlation coefficient or the Spearman
nonparametric correlation were used. A p-value of ,0.05 was
considered statistically significant. Analyses were performed using
SPSS software.
Results
Clinical and Histological Data
We evaluated 20 patients enrolled in the aforementioned trial
before and after DHA-250 treatment (18 months) [8]. With regard
to anthropometric and laboratory data (Table 1), total triglycer-
ides, ALT, AST and ISI were significantly reduced after DHA
treatment while no differences were found in BMI, GGT, total
cholesterol, basal glycemia and insulinemia and HOMA-IR.
Finally, the steatosis grade assessed by liver ultrasonography was
strongly ameliorated after DHA treatment (p,0.001). Serum
levels of pro-inflammatory cytokines (IL-1b, IL-6 and TNF-a)
were significantly reduced after DHA treatment.
Before the treatment, the biopsies were classified in accordance
to the NASH CNR criteria [14,23], into 4 distinct groups
(Supplementary Figure 1): not-SH (N=3), definite-SH or
NASH (N=12), borderline zone1 pattern (N= 1), and borderline
zone3 pattern (N= 4). NAS scores ranged from 1 to 7. PNHS
scores ranged from 1.60 to 100. Fibrosis of some degree was seen
in all biopsy samples: stage 1c in 9 samples, stage 2 in 10, and stage
3 in 1. Control biopsy samples had normal histological features.
After the treatment with DHA, the classification of biopsies
indicated a decrease of definite-SH or NASH diagnosis (N= 3) and
an increase of not-SH diagnosis (N=15).
Moreover, NAS (t = 5.69; p,0.001), PNHS score (t = 2.61; p,
0.05), steatosis (t = 4.86; p,0.001), ballooning (t = 5.34; p,0.001)
and lobular inflammation (t = 2.35; p,0.05) were significantly
reduced (Table 2), while no differences were found in fibrosis.
Table 1. Anthropometric and laboratory parameters of the
study-population.
Before DHA
Treatment
After DHA
treatment
Paired-samples
T Test (p-value)
Sex (M/F) 11/9 11/9 –
Age (years) 10.162.0 12.362.0 ,0.001*
Weight (kg) 57.169.9 59.869.9 ,0.001*
Height (cm) 151617 165616 ,0.001*
BMI (kg/m2) 26.162.5 25.6362.2 0.072
Cholesterol (mg/dL) 172.1611.2 169.6612.9 0.729
Triglycerides (mg/
dL)
91.9630.1 78.8617.7 0.048*
ALT (U/L) 65.4621.3 38.966.2 0.001*
AST (U/L) 50.0615.7 35.465.8 0.007*
GGT (U/L) 21.365.6 19.163.1 0.204
Glucose (mg/dL) 84.966.7 86.663.7 0.328
Insulin (mU/mL) 14.768.1 12.064.8 0.057
HOMA-IR 3.161.8 2.561.0 0.089
ISI 3.060.5 3.460.5 0.038*
TNF-alpha (pg/mL) 19.8563.32 5.8962.09 ,0.001*
IL-6 (pg/mL) 12.5561.32 5.8562.23 ,0.001*
IL-1B (pg/mL) 25.1061.46 8.8762.86 ,0.001*
US 2.660.5 1.360.6 ,0.001*
Data are reported as Means 6 SD * = p,0.05.
doi:10.1371/journal.pone.0088005.t001
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Effect of DHA Treatment on HPCs in pNAFLD Biopsy
Samples
Before treatment, the pNAFLD biopsy samples showed an
expanded DR (0.5960.20) compared with those of normal livers
(0.2160.07, p,0.01). After DHA treatment, the DR expansion
was reduced when a test for paired samples was applied (t = 3.521,
p,0.01; Figure 1A/C). Moreover, DR was correlated with NAS
(r = 0.458; p,0.05) and PNHS scores (r = 0.478; p,0.05) and with
ballooning (r = 0.526; p,0.05) but not with fibrosis, hepatic
steatosis or lobular inflammation.
Then, we evaluated the number of EpCAM-positive cells per
HPF (Figure 1B/C). EpCAM is considered a specific marker of
activated HPCs and several lines of evidence indicated that
EpCAM expression is tightly regulated and only occurs in case of a
temporary need for proliferation and is immediately down-
regulated upon terminal differentiation [24,25]. Before treatment,
pNAFLD biopsy samples showed an expanded number of
EpCAM-positive HPCs (11.6465.24) compared with those of
normal livers (3.5461.15; p,0.01). After DHA treatment, the
number of EpCAM-positive HPCs was statistically reduced when
a test for paired samples was applied (t = 4.102, p,0.01).
Consistently, the number of EpCAM-positive HPCs was strictly
correlated with the extension of DR (r = 0.625; p,0.01).
Moreover, the number of EpCAM-positive HPCs was strictly
correlated with NAS (r = 0.606; p,0.01) and PNHS scores
(r = 0.595; p,0.01), with hepatic steatosis (r = 0.499; p,0.05)
Figure 1. Immunohistochemistry for Cytokeratin(CK) 7 and EpCAM in liver biopsies of pediatric NAFLD patients. A) at the beasline,
pediatric NAFLD biopsies were characterized by a prominent expansion of hepatic progenitor cell (HPC) pool and the presence of reactive ductules at
the periphery of portal spaces. After DHA treatment, a minimal involvement of the HPC compartment was present. Original magnification 206. B)
EpCAM-positive HPCs (arrows) were significant reduced by DHA treatment in comparison with the biopsies at the baseline. Original magnification
406. C) Histograms show the reduction of HPC expansion (ductular reaction extension) and activation (number of EpCAM+ cells) after DHA
treatment. Data are shown as Means 6 Standard Deviation. * = p,0.05.
doi:10.1371/journal.pone.0088005.g001
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and ballooning (r = 0.683; p = 0.01) but not with fibrosis or lobular
inflammation. Taking in account the diagnostic categories, the
number of EpCAM-positive HPCs was significantly lower in not-
SH in comparison with biopsies with definite-SH diagnosis
(t = 2.704; p,0.02).
As regard clinical parameters, DR extension and the number of
EpCAM-positive HPCs were correlated with ALT (r = 0.467; p,
0.05 and r = 0.657; p,0.01, respectively) and with the steatosis
grade assessed by liver ultrasonography (r = 0.490; p,0.05 and
r = 0.632; p,0.01, respectively).
GPR120 Expression and its Correlation with Histo-
pathological Parameters
In liver biopsies, GPR120 was expressed by hepatocytes,
cholangiocytes, HPCs and MW/KC pool as seen both in IHC
sections and through double IF with specific cell markers
(Figures 2, 3).
GPR120 was also expressed by HPCs as shown in serial sections
and in double IF staining (Figure 2A/B). No significant
differences were found comparing pNAFLD biopsies before and
after DHA treatment. However, considering all pNAFLD biopsy
samples, the overall GPR120 expression by HPCs was inversely
correlated with the presence of intermediate hepatocytes (r =2
0.496, p,0.05), NAS score (r =20.501, p,0.05) and steatosis
(r =20.575, p=0.01).
With regard GPR120 expression in hepatocytes (Figure 2C), a
higher expression of GPR120 was observable (2.3360.88) in
biopsies after DHA treatment when compared with pre-treatment
biopsies (1.5861.08; t =23.00; p,0.05). Moreover, when the
diagnostic categories were taken in account, the number of
GPR120 expression in hepatocytes was significantly higher in not-
SH in comparison with biopsies with definite-SH diagnosis (t =2
2.223; p,0.05). In addition, the expression of GPR120 by
hepatocytes was correlated with basal glycemia (r =20.505, p,
0.05).
The number of GPR120-positive MW/KC has been evaluated
in IHC sections and by double IF with the specific marker, CD68
(Figure 3). CD68 clearly and specifically recognized MW/KC in
liver sinusoids but was consistently negative in other liver cells.
Evaluation of GPR120 expression showed that the number of
MW/KC expressing GPR120 per HPF was increased in pNAFLD
patients (8.2563.47) in comparison with normal livers (2.8361.47,
p,0.01). Moreover, a significant reduction (Figure 3) in the
number of GPR120-positive MW/KC (4.0862.97) within the liver
(t = 4.20; p,0.01) was observable after the treatment with DHA.
Interestingly, the number of GPR120-positive MW/KC per
HPF was directly correlated with serum levels of pro-inflammatory
cytokines (TNF-alpha r = 0.519, p,0.01; IL-6: r = 0.670, p,0.001
and IL-1B: r = 0.569, p,0.04: Figure 4C). In addition, the
number of GPR120-positive MW/KC per HPF was inversely
correlated with the presence of intermediate hepatocytes (r =2
0.512, p,0.05).
Phosphorylated(p) NF-kB Expression in Macrophages
and Hepatocytes
As phosphorylation of NF-kB at serine 311 is important for its
TNF-dependent binding to p300 coactivator and recruitment to
target promoters after nuclear translocation, we evaluated p-NF-
kB expression in our patients. We found that p-NF-kB was
expressed by hepatocytes and MW/KCs at cytoplasmic and
nuclear levels (Figures 4A–5A). The percentage of cells, which
displayed a nuclear translocation of p-NF-kB, has been deter-
mined. The percentages of hepatocytes and MW/KCs expressing
p-NF-kB was reduced in pNAFLD patients after the treatment
with DHA (Figure 4B–5B) when the paired-samples T Test was
applied (t = 2.21 and t = 2.94, respectively p,0.05). In addition,
the percentage of p-NF-kB-positive hepatocytes was directly
correlated with NAS, ductular reaction and activation of HPCs
(p,0.05), whereas the macrophage expression of p-NF-kB was
correlated with NAS and ductular reaction extension (p,0.05).
Interestingly, the nuclear expression of p-NF-kB in macrophages
was strongly correlated with serum levels of pro-inflammatory
cytokines (TNF-a: r = 0.585; p,0.001; IL-6: r = 0.467, p,0.01;
IL-1B: r = 0.547, p,0.001, Figure 4D). Finally, the number of
GPR120-positive macrophages was correlated with the expression
of p-NF-kB (r = 0.384; p,0.05).
Discussion
This is the first follow-up study demonstrating the liver specific
effects of 18-months treatment with DHA in pNAFLD which (i)
improves hepatic steatosis, ballooning, inflammation NAS and
PNHS scores but was ineffective on fibrosis; (ii) causes a
remarkable reduction of DR and HPC activation strongly
associated with NAS and PNHS scores; (iii) induces a reduction
of GPR120-positive inflammatory MW/KCs and an increase of
GPR120-positive hepatocytes; and (iv) downregulates nuclear
translocation rate of phosphorylated form of p65NF-kB in
hepatocytes and liver macrophages.
In a recently completed randomized clinical trial, we found that
a 24-months supplementation with DHA was able to determine a
decrease in liver fat [9]. Clinically speaking, in pediatric cohort of
this study, decreases at 18-months in total triglycerides, ALT, AST
and ISI were observed in DHA-supplemented children but their
estimates were imprecise and larger sample sizes are needed to
adequately estimate these effects. In the present study, DHA
Table 2. Histo-pathologic evaluation of the study-population.
Before DHA
Treatment After DHA treatment
Paired-samples
T Test (p-value)
Steatosis 1.7061.08 0.5060.61 ,0.001
Ballooning 0.8560.67 0.2560.44 ,0.001
Lobular inflammation 1.1560.59 0.8560.37 ,0.05
NAS 3.7061.78 1.6061.05 ,0.01
PNHS 71.31640.84 5.868.3 ,0.05
Fibrosis 1.6060.60 1.4560.76 = 0.481
Data are reported as Means 6 SD.
doi:10.1371/journal.pone.0088005.t002
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treatment ameliorated hepatocyte steatosis, ballooning, NAS and
PNHS scores. Taking in account the diagnostic category, no
treated patient had a progression of the histo-pathological
damaging and a worse diagnosis at the biopsy after the 18-months
therapy. Moreover, 13/17 patients, which were classified as
definite SH or borderline before the treatment, presented a more
positive diagnosis after the treatment.
A limitation of the present study could be represented by the
lack of biopsies from a placebo group. In the completed
randomized clinical trial, clinical, laboratory and liver ultrasound
data were used to discriminate effects between DHA treated and
placebo groups [26]. Indeed, considering that patients were
children, the placebo group did not receive liver biopsy at 18
months.
LC-PUFAs exert their actions by the modulation of GPR120
[10,27]. Here, we showed that GPR120 was expressed by several
cell types in human liver as MWs/KCs within sinusoids,
hepatocytes and HPCs. Accordingly, the clinical effects and the
histo-pathological changes after DHA treatment in pNAFLD
patients could be determined through the DHA action on all these
different cells.
GPR120 has been indicated as a lipid-sensing receptor highly
expressed in proinflammatory macrophages [10]. By signaling
through GPR120, DHA mediates potent anti-inflammatory effects
by inhibiting both Toll-Like Receptor (TLR) and Tumor Necorsis
Factor(TNF)-a signaling pathways [10,27]. Moreover, GPR120
seems to have a key role in counter-inflammation representing a
feedback signal that blocks NF-kB phosphorylation [27,28]. Our
Figure 2. GPR120 expression by HPC and Hepatocytes in pediatric NAFLD patients. A) Immunohistochemistry for EpCAM and GPR120 in
serial sections of pediatric NAFLD biopsies. CK-7-positive HPCs highly express GPR120 (arrows). B) Double immunofluorescence for EpCAM (green)
and GPR120 (red) in NAFLD biopsies. Nuclei are shown in blue. Numerous EpCAM-positive progenitor cells co-express GPR120 (yellow cells: yellow
arrows) confirming the findings obtained through immunohistochemistry in serial sections. C) Immunohistochemistry for GPR120 in sections of
pediatric NAFLD biopsies before and after DHA treatment. A significant increase of GPR120-positive hepatocytes was clearly seen after DHA
treatment. Original magnification: 406.
doi:10.1371/journal.pone.0088005.g002
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results were in accordance with this scenario. In pNAFLD, the
number of GPR120-positive (inflammatory) MW/KCs was
increased in comparison with normal. Interestingly, DHA
treatment induced a significant reduction of GPR120-positive
MW/KC pool that matched with a strong decrease of macro-
phages expressing serine 311 phosphorylated form of NF-kB at
nuclear level. These results suggested that, in pNAFLD, DHA
treatment was able to reduce the inflammatory macrophage pool
and induce an anti-inflammatory macrophage polarization. Two
distinct modes of macrophage activation were proposed to
differentiate between M1 and M2 macrophages [29]. M1-
macrophages produce pro-inflammatory cytokines such as Inter-
leukin (IL)-1b, IL-6, IL- 8, IL-12, and TNF-a. Macrophage can be
polarized toward alternative activation phenotype (M2) which has
a role in promoting wound healing through the releasing of anti-
inflammatory cytokines and the promotion of a efficient clearance
of apoptotic cells [30].
In keeping, GPR120 macrophage expression was strongly
correlated with the serum levels of pro-inflammatory cytokines
(TNF-a, IL-6 and IL-1b). These data seem to confirm that, in
pNAFLD, GPR120-positive macrophages within the liver are
responsible of pro-inflammatory cytokine production and the
treatment with DHA could switch the macrophage polarization
via the modulation of NF-kB pathway.
DHA treatment caused a decrease of DR and HPC activation
that was strongly correlated with the improvement of clinical and
imaging parameters, hepatocyte steatosis and ballooning, NAS
and PNHS. Noteworthy, the activation of HPC compartment was
higher in definite steatohepatitis compared with not steatohepatitis
biopsies. Taken together, these results highlight the pivotal role of
Figure 3. GPR120 expressions by Macrophages in pediatric NAFLD patients. A) Immunohistochemistry for GPR120 in sections of pediatric
NAFLD biopsies. B) Double immunofluorescence for CD68 (red) and GPR120 (green) in NAFLD biopsies. Nuclei are shown in blue. CD68-positive
macrophages express GPR120 (yellow arrows). Original magnification: 406. C) The histogram shows the number of GPR120-positive macrophages
per high power field (HPF) at the baseline and after DHA treatment. A significant reduction of GPR120-positive macrophages was seen after DHA
treatment. * = p,0.05.
doi:10.1371/journal.pone.0088005.g003
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HPC activation in pNAFLD and its potential impact on the
progression towards NASH.
Recently, we demonstrated that HPC expansion, especially in
children with NASH, is associated with the degree of liver injury,
hepatocyte apoptosis, and cell-cycle arrest [3]. In general, the local
microenvironment has a key role in achieving a defined progenitor
specification in response to diverse injuries [20,31]. Recently,
macrophages have been indicated as a key component of HPC
niche [31]; during hepatocyte regeneration, an inefficient effer-
ocytosis of hepatocyte debris could be able to induced Wnt3a
expression by macrophages; this resulted in canonical Wnt
signaling in nearby HPCs, thus promoting their specification to
hepatocytes [31]. Interestingly, in the present study, the presence
of intermediate hepatocytes, a sign of HPC differentiation towards
hepatocyte fate, was correlated with the number of GPR120-
positive macrophages. In this context, DHA could exert a dual
effect on HPC niche acting directly on HPCs by GPR120
modulation or indirectly on macrophage polarization [20,32].
Figure 4. Nuclear expression of phosphorylated (p) NF-kB by Macrophages in pediatric NAFLD patients. A) Immunohistochemistry for
serine-311-phosphorylated NF-kB (pNF-kB) in pediatric NAFLD biopsies before and after DHA treatment. In parallel with GPR120 expression, the DHA
treatment determined a reduction of pNF-kB expression and its nuclear translocation in macrophages (A, yellow arrows). Original magnification: 406.
B) Histogram shows the significant reduction of pNF-kB nuclear translocation in macrophages after DHA treatment. Data are shown as Means 6
Standard Deviation. * = p,0.05. C–D) The number of GPR120-positive macrophages (C) and the pNF-kB nuclear expression in macrophages. (D) were
correlated with serum level of inflammatory cytokines.
doi:10.1371/journal.pone.0088005.g004
Figure 5. Nuclear expression of phosphorylated (p) NF-kB by hepatocytes in pediatric NAFLD patients. A) Immunohistochemistry for
pNF-kB in pediatric NAFLD biopsies demonstrates the reduction of pNF-kB in hepatocyte nuclei (red arrows) after DHA treatment. B) DHA treatment
determined a significant reduction of pNF-kB expression and its nuclear translocation in hepatocytes. Data are shown as Means 6 Standard
Deviation. * = p,0.05.
doi:10.1371/journal.pone.0088005.g005
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Our results indicated that GPR120 hepatocyte expression was
highly enhanced by treatment with DHA and was higher in not
steatohepatitis in comparison with definite SH biopsies. Parallel,
DHA determined a reduction of pNF-kB in hepatocyte nuclei.
The activation of TLR4 signaling in hepatocytes, accompanied
with the relocation of NF-kB into the nucleus, was proven to play
an important role during the initiation of NAFLD [33,34]. Our
data showed that the nuclear expression of pNF-kB in hepatocytes
was correlated with the serum levels of pro-inflammatory
cytokines, thus suggesting that NF-kB activation and its modula-
tion in hepatocytes could have a role in liver and systemic
inflammatory status.
In conclusion, our results highlight the anti-inflammatory effects
of DHA administration in pNAFLD and the liver-resident cells
which could be stimulated through the interaction with GPR120-
mediated NF-kB pathway. Furthermore, in this scenario, LC-
PUFA-mediated modulation of GPR120 exploits a novel crucial
role in the regulation of the cell-to-cell cross-talk that controls lipid
homeostasis, insulin sensitivity, danger recognition and immune
tolerance response.
Supporting Information
Figure S1 Histopathological aspects of pediatric NAFLD
biopsies. A) The different diagnostic categories in which biopsies
were characterized were showed: definite steatohepatitis (Nash:
NAS Score $5); Nash Borderline (NAS Score = 3–4); Not-
steatohepatitis (Not Nash: NAS score = 1–2); B) liver biopsies at
baseline and after DHA treatment. Steatosis and ballooning were
significantly reduced after the DHA treatment. Hematoxylin-
Eosin. Original Magnification: 10X. C) Histo-pathological evalu-
ation: NAS, steatosis, ballooning, and lobular inflammation were
significantly reduced after the DHA treatment while no differences
were found in fibrosis. * = p,0.05.
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